During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
|Videos|February 27, 2020
A 72-Year-Old Man With Symptomatic Follicular Lymphoma
A 72-Year-Old Man With Symptomatic Follicular Lymphoma
Advertisement
Case: A 72-Year-Old Man With Symptomatic Follicular Lymphoma
Initial Presentation
A 72-year-old man presented to his physician with fatigue, and an involuntary 9-lb weight loss over the last 3 months. He complained of intermittent night sweats and decrease activities of daily living
Clinical work-up
- PE: Splenomegaly, firm nontender, rubbery lymph nodes on palpation in left axillary and bilateral inguinal region
- CBC: WBC, 13.6 X 104/L, platelets, 114 X 109/L, Hb, 8.9 g/dL, LDH, 380 U/L
- Beta 2 microglobulin 3.4 µg/mL
- HIV, HBV-, HCV-negative
- Excisional biopsy showed grade 3 follicular lymphoma; CD10+, CD23+
- Bone marrow biopsy; 50% involved
- PET/CT showed widespread lymphadenopathy above and below the diaphragm: largest lymph node measuring 7.6 cm, spleen measuring at 12.3 cm
- Diagnosis: Grade 3A, Stage IVB follicular lymphoma
- FLIPI2 score: high-risk
- ECOG PS 1
Treatment
- Patient started on obinutuzumab + CVP q8W of 21-day cycles
- Post-therapy PET showed partial response
- Continued on obinutuzumab 1000 mg q8W for 12 doses as monotherapy, well-tolerated
Follow-up
- PET scan at 12 months was negative
- Completed treatment; after 24 months of obinutuzumab maintenance remains in on-going remission
Advertisement
Related to this article
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Eftilagimod alfa plus pembrolizumab and radiotherapy yielded 81.1% disease-free survival at 12 months in patients with resectable soft tissue sarcoma.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
During a live event, Theresa Medina, MD, and participants discussed how disease site, BRAF status, and prior therapy guide treatment selection in metastatic melanoma.
The FDA has approved the PCR-based OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors for treatment with pembrolizumab.
Advertisement
Advertisement
Trending on Targeted Onc
1
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
2
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
3
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
4
Novocure’s Optune Mya Gets FDA Not Approvable Letter
5